计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| rp144120-10μg |
10μg |
现货 ![]() |
| |
| rp144120-50μg |
50μg |
现货 ![]() |
| |
| rp144120-100μg |
100μg |
现货 ![]() |
| |
| rp144120-1mg |
1mg |
期货 ![]() |
|
| 产品名称 | Recombinant Human B7-1/CD80 Protein |
|---|---|
| 别名 | B-淋巴细胞激活抗原B7-1(LAB7-1)活性蛋白 | 重组人 B7-1/CD80 蛋白 |
| 英文别名 | Activation B7-1 antigen | B7 | BB1 | CTLA-4 counter-receptor B7.1 | Activation B7-1 antigen | B lymphocyte activation antigen B7 | B7 | B7-1 | B7-1 antigen | B7.1 | BB1 | CD28 antigen ligand 1 | CD28LG | CD28LG1 | CD80 | CD80 antigen | CD80 antigen (CD28 |
| 规格或纯度 | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥95%(SDS-PAGE) |
| 产品介绍 |
Purity |
| 生物活性 | Immobilized Recombinant Human B7-1/CD80 Protein (rp144120) at 2.0 μg/mL can bind Recombinant human CTLA-4 with a linear range of 7.0 - 62.0 ng/mL. The EC50 for this effect is 23.47 ng/mL. |
| 内毒素水平 | <0.1 EU/μg |
| 表达系统 | HEK293 |
| 种属 | 人(Human) |
| 氨基酸 | 35-242 aa |
| 序列 | VIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGEELNAINTTVSQDPETELYAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTTKQEHFPDNHHHHHH |
| 纯度 | ≥95% (SDS-PAGE) |
| 蛋白标签 | C-His |
| 无载体 | Yes |
| 无动物源 | Yes |
| Accession # | P33681 |
| 来源 | 重组表达 |
| 预测分子量 | 25 kDa |
| SDS-PAGE | 40 - 55 kDa, under reducing conditions; 40 - 55 kDa, under non-reducing conditions. |
| 物理形态 | 冻干(Lyophilized) |
|---|---|
| 储存缓冲液 | Lyophilized from 10mM PBS, 5% Trehalose, 5% Mannitol, pH 7.4 |
| 复溶 | Reconstitute in sterile water to a concentration of 0.1-0.5 mg/ml. |
| 储存温度 | -20°C储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -20~-80℃ 下可保存 1 年以上。收货后建议分装。避免冷冻/解冻循环。 |
| 分子类型 | 蛋白质 |
Recombinant Human B7-1/CD80 Protein (rp144120) - Protein Bioactivity
Immobilized Recombinant Human B7-1/CD80 Protein (rp144120) at 2.0 μg/mL can bind Recombinant human CTLA-4 with a linear range of 7.0 - 62.0 ng/mL. The EC50 for this effect is 23.47 ng/mL.
Recombinant Human B7-1/CD80 Protein (rp144120) - SDS-PAGE
3 μg/lane of Recombinant Human B7-1/CD80 Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 40 - 55 kDa.
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | rp144120 | |
| 分析证书 | rp144120 | |
| 分析证书 | rp144120 | |
| 分析证书 | rp144120 | |
| 分析证书 | rp144120 | |
| 分析证书 | rp144120 |
¥639.92
| 1. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334] |
| 2. Vicente Rabaneda EF, Herrero-Beaumont G, Castañeda S. (2013) Update on the use of abatacept for the treatment of rheumatoid arthritis.. Expert Rev Clin Immunol, 9 (7): (599-621). [PMID:23899231] |
| 3. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7.. J Exp Med, 174 (3): (561-9). [PMID:1714933] |
| 4. Selvakumar, A A and 5 more authors.. (1992) Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7.. Immunogenetics, [PMID:1377173] |
| 5. Freeman, G J GJ and 8 more authors.. (1991) Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7.. The Journal of experimental medicine, (1): [PMID:1714935] |
| 6. Freeman, G J GJ and 5 more authors.. (1989) B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:2794510] |
| 7. Lanier, L L LL and 7 more authors.. (1995) CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:7527824] |
| 8. Vandenborre, K K and 5 more authors.. (1999) Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.. Immunology, [PMID:10583602] |
| 9. Ikemizu, S S and 7 more authors.. (2000) Structure and dimerization of a soluble form of B7-1.. Immunity, [PMID:10661405] |
| 10. Gottlieb, Alice B AB and 8 more authors.. (2004) Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.. Clinical immunology (Orlando, Fla.), [PMID:15093549] |
| 11. Czuczman, Myron S MS and 13 more authors.. (2005) Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (1): [PMID:15994148] |
| 12. and Kremer, Joel M JM.. (2005) Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis.. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, [PMID:16357751] |
| 13. Hervey, Pauline S PS and Keam, Susan J SJ.. (2006) Abatacept.. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, [PMID:16573350] |
| 14. Muzny, Donna M DM and 113 more authors.. (2006) The DNA sequence, annotation and analysis of human chromosome 3.. Nature, (27): [PMID:16641997] |
| 15. Weyand, Cornelia M CM and Goronzy, Jörg J JJ.. (2006) T-cell-targeted therapies in rheumatoid arthritis.. Nature clinical practice. Rheumatology, [PMID:16932686] |
| 16. and Scheinfeld, Noah N.. (2006) Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.. The Journal of dermatological treatment, [PMID:16971318] |
| 17. Tedesco Silva, Helio H, Pinheiro Machado, Paula P, Rosso Felipe, Claudia C and Medina Pestana, Jose Osmar JO.. (2006) Immunotherapy for De Novo renal transplantation: what's in the pipeline?. Drugs, [PMID:16978033] |
| 18. Vincenti, Flavio F and Luggen, Michael M.. (2007) T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation.. Annual review of medicine, [PMID:17020493] |
| 19. Nogid, Anna A and Pham, David Q DQ.. (2006) Role of abatacept in the management of rheumatoid arthritis.. Clinical therapeutics, [PMID:17212998] |
| 20. Leonard, J P JP and 14 more authors.. (2007) A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.. Annals of oncology : official journal of the European Society for Medical Oncology, [PMID:17470451] |
| 21. Kakoulidou, M M, Giscombe, R R, Zhao, X X, Lefvert, A K AK and Wang, X X.. (2007) Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation.. Scandinavian journal of immunology, [PMID:17953528] |
| 22. Reynolds, Jennifer J, Shojania, Kam K and Marra, Carlo A CA.. (2007) Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.. Pharmacotherapy, [PMID:18041889] |
| 23. Maxwell, Lara J LJ and Singh, Jasvinder A JA.. (2010) Abatacept for rheumatoid arthritis: a Cochrane systematic review.. The Journal of rheumatology, [PMID:20080922] |
| 24. Kleinpeter, Patricia and 20 more authors.. (2019) By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.. Journal of virology, (1): [PMID:30918073] |